- Home
- GXAI vs RNAZ Comparison
GXAI vs RNAZ Comparison
Compare GXAI & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GXAI
- RNAZ
- Stock Information
- Founded
- GXAI 2021
- RNAZ 2016
- Country
- GXAI United States
- RNAZ United States
- Employees
- GXAI N/A
- RNAZ N/A
- Industry
- GXAI
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- GXAI
- RNAZ Health Care
- Exchange
- GXAI Nasdaq
- RNAZ Nasdaq
- Market Cap
- GXAI 9.3M
- RNAZ 7.8M
- IPO Year
- GXAI 2023
- RNAZ 2021
- Fundamental
- Price
- GXAI $1.33
- RNAZ $8.99
- Analyst Decision
- GXAI
- RNAZ Strong Buy
- Analyst Count
- GXAI 0
- RNAZ 1
- Target Price
- GXAI N/A
- RNAZ $280.00
- AVG Volume (30 Days)
- GXAI 131.3K
- RNAZ 13.2K
- Earning Date
- GXAI 11-13-2025
- RNAZ 11-14-2025
- Dividend Yield
- GXAI N/A
- RNAZ N/A
- EPS Growth
- GXAI N/A
- RNAZ N/A
- EPS
- GXAI N/A
- RNAZ N/A
- Revenue
- GXAI $694,278.00
- RNAZ N/A
- Revenue This Year
- GXAI N/A
- RNAZ N/A
- Revenue Next Year
- GXAI N/A
- RNAZ N/A
- P/E Ratio
- GXAI N/A
- RNAZ N/A
- Revenue Growth
- GXAI 23205.74
- RNAZ N/A
- 52 Week Low
- GXAI $1.00
- RNAZ $6.15
- 52 Week High
- GXAI $7.50
- RNAZ $468.44
- Technical
- Relative Strength Index (RSI)
- GXAI 45.18
- RNAZ 42.28
- Support Level
- GXAI $1.04
- RNAZ $8.48
- Resistance Level
- GXAI $1.29
- RNAZ $9.41
- Average True Range (ATR)
- GXAI 0.12
- RNAZ 0.47
- MACD
- GXAI 0.01
- RNAZ 0.11
- Stochastic Oscillator
- GXAI 54.29
- RNAZ 61.11
About GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.